Cargando…
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
Niraparib (Zejula™) is a PARP inhibitor which is approved for maintenance therapy in adults with advanced ovarian cancer in complete or partial response to platinum-based chemotherapy. In a placebo-controlled phase III trial in patients with newly diagnosed advanced ovarian cancer, niraparib signifi...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613118/ https://www.ncbi.nlm.nih.gov/pubmed/34635996 http://dx.doi.org/10.1007/s11523-021-00841-2 |
_version_ | 1784603570798067712 |
---|---|
author | Lee, Arnold |
author_facet | Lee, Arnold |
author_sort | Lee, Arnold |
collection | PubMed |
description | Niraparib (Zejula™) is a PARP inhibitor which is approved for maintenance therapy in adults with advanced ovarian cancer in complete or partial response to platinum-based chemotherapy. In a placebo-controlled phase III trial in patients with newly diagnosed advanced ovarian cancer, niraparib significantly extended progression free survival in two predefined populations, namely a patient population with altered homologous-recombination DNA repair pathways [i.e. homologous-recombination deficiency positive (HRd)] and the overall trial population. A prespecified exploratory subgroup analysis indicated that niraparib was also efficacious in patients who were homologous recombination deficiency negative or homologous recombination proficient (HRp). Niraparib has a manageable tolerability profile with myelosuppression as the main safety concern. Haematological reactions were managed with monitoring and dose reduction or interruption. A weight- and platelet count-based individualised dosage regimen introduced during the trial (and subsequently approved) appeared to improve haematological tolerability. Niraparib is a useful option for first-line maintenance therapy for advanced ovarian cancer in adults who responded to platinum-based chemotherapy, regardless of homologous-recombination deficiency status and is a promising option for HRp patients, for whom maintenance treatment options are limited. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11523-021-00841-2. |
format | Online Article Text |
id | pubmed-8613118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-86131182021-12-10 Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer Lee, Arnold Target Oncol Adis Drug Evaluation Niraparib (Zejula™) is a PARP inhibitor which is approved for maintenance therapy in adults with advanced ovarian cancer in complete or partial response to platinum-based chemotherapy. In a placebo-controlled phase III trial in patients with newly diagnosed advanced ovarian cancer, niraparib significantly extended progression free survival in two predefined populations, namely a patient population with altered homologous-recombination DNA repair pathways [i.e. homologous-recombination deficiency positive (HRd)] and the overall trial population. A prespecified exploratory subgroup analysis indicated that niraparib was also efficacious in patients who were homologous recombination deficiency negative or homologous recombination proficient (HRp). Niraparib has a manageable tolerability profile with myelosuppression as the main safety concern. Haematological reactions were managed with monitoring and dose reduction or interruption. A weight- and platelet count-based individualised dosage regimen introduced during the trial (and subsequently approved) appeared to improve haematological tolerability. Niraparib is a useful option for first-line maintenance therapy for advanced ovarian cancer in adults who responded to platinum-based chemotherapy, regardless of homologous-recombination deficiency status and is a promising option for HRp patients, for whom maintenance treatment options are limited. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11523-021-00841-2. Springer International Publishing 2021-10-11 2021 /pmc/articles/PMC8613118/ /pubmed/34635996 http://dx.doi.org/10.1007/s11523-021-00841-2 Text en © Springer Nature 2021, corrected publication 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Adis Drug Evaluation Lee, Arnold Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer |
title | Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer |
title_full | Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer |
title_fullStr | Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer |
title_full_unstemmed | Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer |
title_short | Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer |
title_sort | niraparib: a review in first-line maintenance therapy in advanced ovarian cancer |
topic | Adis Drug Evaluation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613118/ https://www.ncbi.nlm.nih.gov/pubmed/34635996 http://dx.doi.org/10.1007/s11523-021-00841-2 |
work_keys_str_mv | AT leearnold niraparibareviewinfirstlinemaintenancetherapyinadvancedovariancancer |